Literature DB >> 15081922

Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry.

Kyunghwa Hwang1, Milin R Acharya, Edward A Sausville, Suoping Zhai, Eunhee W Woo, Jürgen Venitz, William D Figg, Alex Sparreboom.   

Abstract

A rapid method was developed for the quantitative determination of the novel histone deacetylase inhibitor, MS-275, in human plasma. Calibration curves were constructed in the range of 1-100 ng/ml, and were analyzed using a weight factor proportional to the nominal concentration. Sample pretreatment involved a one-step protein precipitation with acetonitrile of 0.1 ml samples. The analysis was performed on a column (75 mm x 4.6 mm i.d.) packed with 3.5 microm Phenyl-SB material, using methanol-10mM ammonium formate (55:45 (v/v)) as the mobile phase. The column effluent was monitored by mass spectrometry with positive electrospray ionization. The values for precision and accuracy were always < or =5.58 and <11.4% relative error, respectively. The method was successfully applied to examine the pharmacokinetics of MS-275 in a cancer patient.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15081922     DOI: 10.1016/j.jchromb.2004.01.023

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  6 in total

1.  A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma.

Authors:  Ming Zhao; Michelle A Rudek; Aleksandr Mnasakanyan; Carol Hartke; Roberto Pili; Sharyn D Baker
Journal:  J Pharm Biomed Anal       Date:  2006-09-12       Impact factor: 3.935

2.  Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.

Authors:  Ivana Gojo; Anchalee Jiemjit; Jane B Trepel; Alex Sparreboom; William D Figg; Sandra Rollins; Michael L Tidwell; Jacqueline Greer; Eun Joo Chung; Min-Jung Lee; Steven D Gore; Edward A Sausville; James Zwiebel; Judith E Karp
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

3.  Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer.

Authors:  Milin R Acharya; Judith E Karp; Edward A Sausville; Kyunghwa Hwang; Qin Ryan; Ivana Gojo; Jurgen Venitz; William D Figg; Alex Sparreboom
Journal:  Invest New Drugs       Date:  2006-09       Impact factor: 3.850

4.  A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas.

Authors:  Lia Gore; Mace L Rothenberg; Cindy L O'Bryant; Mary Kay Schultz; Alan B Sandler; Denise Coffin; Candice McCoy; Astrid Schott; Catherine Scholz; S Gail Eckhardt
Journal:  Clin Cancer Res       Date:  2008-06-25       Impact factor: 12.531

5.  Determination of a benzamide histone deacetylase inhibitor, MS-275, in human plasma by liquid chromatography with mass-spectrometric detection.

Authors:  Matthew Danish; Erin R Gardner; Xiaohong Chen; William D Figg
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-12-13       Impact factor: 3.205

6.  A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phase-Clinical Trial Network (PEP-CTN).

Authors:  Andrew Bukowinski; Bill Chang; Joel M Reid; Xiaowei Liu; Charles G Minard; Jane B Trepel; Min-Jung Lee; Elizabeth Fox; Brenda J Weigel
Journal:  Pediatr Blood Cancer       Date:  2021-01-12       Impact factor: 3.838

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.